全文获取类型
收费全文 | 2191篇 |
免费 | 175篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 107篇 |
妇产科学 | 33篇 |
基础医学 | 258篇 |
口腔科学 | 88篇 |
临床医学 | 220篇 |
内科学 | 433篇 |
皮肤病学 | 51篇 |
神经病学 | 85篇 |
特种医学 | 292篇 |
外科学 | 338篇 |
综合类 | 40篇 |
预防医学 | 110篇 |
眼科学 | 69篇 |
药学 | 63篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 191篇 |
出版年
2021年 | 31篇 |
2020年 | 26篇 |
2019年 | 27篇 |
2018年 | 49篇 |
2017年 | 30篇 |
2016年 | 29篇 |
2015年 | 50篇 |
2014年 | 55篇 |
2013年 | 99篇 |
2012年 | 92篇 |
2011年 | 85篇 |
2010年 | 93篇 |
2009年 | 82篇 |
2008年 | 65篇 |
2007年 | 81篇 |
2006年 | 75篇 |
2005年 | 64篇 |
2004年 | 61篇 |
2003年 | 73篇 |
2002年 | 61篇 |
2001年 | 49篇 |
2000年 | 40篇 |
1999年 | 50篇 |
1998年 | 93篇 |
1997年 | 91篇 |
1996年 | 68篇 |
1995年 | 61篇 |
1994年 | 50篇 |
1993年 | 51篇 |
1992年 | 25篇 |
1991年 | 42篇 |
1990年 | 38篇 |
1989年 | 71篇 |
1988年 | 52篇 |
1987年 | 39篇 |
1986年 | 34篇 |
1985年 | 30篇 |
1984年 | 25篇 |
1983年 | 24篇 |
1982年 | 20篇 |
1981年 | 15篇 |
1980年 | 20篇 |
1979年 | 15篇 |
1978年 | 15篇 |
1977年 | 14篇 |
1976年 | 13篇 |
1975年 | 11篇 |
1971年 | 12篇 |
1970年 | 10篇 |
1966年 | 10篇 |
排序方式: 共有2388条查询结果,搜索用时 15 毫秒
61.
Fevzi Akinci Joseph Coyne Bernard Healey Joni Minear 《Disease Management & Health Outcomes》2004,12(5):285-298
When considering the trends in disease management, the focus of healthcare in the US has shifted from communicable diseases, which can most often be managed successfully, to chronic diseases, which are currently not managed very well. Chronic diseases, such as diabetes mellitus, become a lifelong health problem for the individual, the family, and in the workplace. Currently, there is no vaccine to prevent diabetes and no cure for diabetes once acquired. In order to improve the quality of care for diabetes, national performance measures have been developed to provide a unified set of diabetes-specific performance and outcome measures.The Diabetes Quality Improvement Project (DQIP) founded in 1997 through a partnership between the Center for Medicare and Medicaid Services, the National Committee for Quality Assurance, and the American Diabetes Association, established a single, standardized set of performance measures for diabetes care quality improvement and accountability in the US, which were published in 1998. The DQIP measures are noteworthy as a model for many other chronic diseases. Indeed, the DQIP represents the first widely adopted comprehensive performance measurement standards, not just for diabetes but for any single chronic disease. This is of further significance since it was developed by a coalition of public and private entities in the US.In order to prevent long-term complications from diabetes, there needs to be a physician-coordinated treatment plan involving a team approach to the problem. When such a physician-coordinated treatment plan is developed in conformance with the comprehensive performance measures, the prospects for a greater impact on diabetes might be enhanced.Overall, national performance measures for diabetes care have been widely adopted into health plan quality initiatives and have resulted in increased efforts to promote preventative screening and testing. Better compliance has lead to more stringent glucose control and helped to educate the public on the utility of the glycosylated hemoglobin level test for finding those at risk for microvascular and neuropathic complications. While more Americans with diabetes are receiving the recommended standards of care as a result of the implementation of national performance measures, diabetes management remains suboptimal but achievable.The authors concluded from this review that national performance measures have provided health plans and providers with objective tools to measure quality; however, these measures now need to move to prevention standards and initiatives. Policy development for diabetes care must continue to move from managing chronic illness to preventative screening of pre-diabetes through to identification and modification of lifestyle risk factors. 相似文献
62.
63.
64.
65.
66.
67.
68.
69.
Low doses of corticosteroid readily reverse the pain and stiffness of polymyalgia rheumatica, but only high doses can prevent the vascular complications of giant cell arteritis. The dilemma of therapy arises from the fact that giant cell arteritis can present subtly, with the same symptoms as polymyalgia rheumatica. Prescribing a high dose for all patients with such symptoms would certainly prevent vascular complications, but it would also put patients with polymyalgia rheumatica at needless risk of steroid side effects. In this article, Drs Wilske and Healey explain how to differentiate between these two inflammatory conditions on clinical and laboratory grounds so that the correct dose of steroid can be more confidently prescribed. 相似文献
70.